Moleculin Biotech posts new corporate presentation
Moleculin Biotech, Inc. filed a current report to note that it is using a new corporate presentation for investors and other audiences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Moleculin Biotech, Inc. filed a current report to note that it is using a new corporate presentation for investors and other audiences. The presentation is posted on the company’s website and is included as Exhibit 99.1 to the report. The company specifies that this material is being furnished under a disclosure item for informational purposes and is not deemed filed under securities laws unless later specifically incorporated by reference.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Moleculin Biotech (MBRX) disclose in this 8-K?
Moleculin Biotech disclosed that it is using a new corporate presentation, which is posted on its website and attached as Exhibit 99.1.
Is the Moleculin Biotech (MBRX) corporate presentation considered filed with the SEC?
The company states the presentation is being furnished under a disclosure item and is not considered "filed" under securities laws unless later specifically incorporated by reference.
Which exhibit contains the new Moleculin Biotech (MBRX) corporate presentation?
The corporate presentation is included as Exhibit 99.1 to the report.
Does this Moleculin Biotech (MBRX) 8-K report any major transaction or earnings results?
No, the report focuses on the use of a new corporate presentation for the company and does not describe major transactions or earnings data.
Why does Moleculin Biotech (MBRX) emphasize that the information is being furnished and not filed?
The company clarifies that information furnished under this disclosure item is not automatically subject to certain legal liabilities or incorporation into other SEC filings unless specifically identified for that purpose.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 20, 2026
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 7.01
|
Regulation FD Disclosure
|
On January 20, 2026, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
Investor Presentation dated January 2026
|
|
104
|
Cover page Interactive Data File (formatted as Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|||
|
Date:
|
January 20, 2026
|
||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||